News

Lundbeckfonden Ventures News

  LA JOLLA, Calif., Feb. 15, 2012 /PRNewswire/ — Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has completed a $43 million equity financing to advance its lead investigational product candidate MYDICAR® for the treatment of heart failure. The financing was led...
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced dosing of the first patient in the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) Phase IIIb study of LCP-TacroT in kidney transplant recipients experiencing drug-induced tremors. The STRATO study is designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard...
Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces the initiation of a Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant problem in patients undergoing major surgery, despite the availability of a range of anti-emetic medications. APD421...
  Lund, Sweden; Lloyd Diamond has been recruited CEO of BONESUPPORT – the Swedish medical technology company with a revolutionary orthobiologic platform for treatment of osteoporotic fractures and deep bone infections. Mr. Diamond replaces Dr. Fredrik Lindberg, the co-founder and present CEO, who will remain in the company as Chief Scientific Officer. By the recruitment...
Bagneux, December 6, 2011 – DBV Technologies announces the arrival of David Schilansky – starting December 19 – as Chief Financial Officer and as such, will supervise all financial activities of the company as well as partnerships and Business Development initiatives. David will be a member of the Executive Committee.“The integration of David Schilansky to...
Cambridge, UK: Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa study of APD209 in cancer cachexia. APD209 comprises a new and patent protected use for an oral combination of two currently marketed drugs and has been designed to increase appetite, muscle...
. Collaboration to leverage Syntaxin and Ipsen’s expertise in the discovery and development of botulinum toxins   Paris (France) and Oxford (UK), 20 October 2011 – Ipsen (Euronext: IPN, ADR: IPSEY) and Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies targeting cell secretion pathways, announced today a global strategic collaboration to explore the discovery...
The Swedish MedTech company BoneSupport is implementing a follow-up share issue with the Danish investment fund Lundbeckfond Ventures. Together with the share issue in June this year, the company has raised totally 170 MSEK during 2011. The company markets CERAMENT T, an injectable biologic that remodels into bone and heals fractures. The raised capital will...
Download press release here: Acacia_Pharma_starts_Phase_II_clinical_trail_f.PDF
1 43 44 45 46 47

Lundbeckfonden Ventures

News

BONESUPPORT™ – POSITIVE RESULTS FROM THE CERTiFy STUDY COMPARING CERAMENT®|BONE VOID FILLER WITH AUTOGRAFT
19. November 2018
Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
14. November 2018
Acacia Pharma Group PLC – ACACIA PHARMA RESUBMITS BARHEMSYS(TM) NEW DRUG APPLICATION
7. November 2018